

# Andrew T Stefka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6057075/publications.pdf>

Version: 2024-02-01

5  
papers

153  
citations

1684188

5  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	1.4	56
2	Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 19.	6.2	40
3	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	1.4	38
4	Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. <i>Cancer Medicine</i> , 2020, 9, 324-334.	2.8	14
5	Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 8513-8513.	1.6	5